Who we are. What we are we doing.
The Psychedelic Business Intelligence (PBI) Summit is a private, executive-level forum focused on the emerging psychedelic economy. Led by Paul Austin and Tom Aarts, this summit will bring together a select group of entrepreneurs, investors, and business leaders to explore the commercial realities of this fast-evolving space. From retreat scalability and clinic economics to investment trends, legal frameworks, and product innovation, the PBI Summit delivers data-driven insight and strategic connections designed to accelerate high-quality business outcomes. With an emphasis on deal flow, market intelligence, and operational excellence, it stands as a premier venue for those building the next generation of psychedelic ventures.
The psychedelics industry is not only expanding — it is shapeshifting before our eyes. This is no longer a fringe conversation, nor a purely academic debate about molecules and brain scans. It is a commercial, cultural, and political movement. Clinics are opening. Retreats are scaling. Consumer demand is rising. Investment is waking up again.
But perhaps most importantly: the rules are still being written.
While Oregon and Colorado were once the sole state-sanctioned models of legal psychedelic access, New Mexico has now joined the vanguard, signaling a continued arc of state-level momentum. Yet this regulatory terrain remains profoundly plastic. The map is redrawn each quarter. What’s true today may be outdated by next week.
This first issue of the Psychedelic Business Journal (PBJ), written by research analyst Molly Pop Elkington, doesn’t pretend to offer a static directory of laws and licenses. Instead, it delivers an on-the-ground, operator-informed business briefing on what’s working and, maybe more importantly, what’s not. We offer interviews with over 30 founders, facilitators, policymakers, and product innovators. We pair that with original consumer data and a clinic-level economic model to unpack the opportunity in this space from every angle.
This is not a science journal. This is a business playbook.
Contact us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!